StockNews.com started coverage on shares of GlycoMimetics (NASDAQ:GLYC – Free Report) in a report issued on Wednesday morning. The firm issued a sell rating on the biotechnology company’s stock.
A number of other equities analysts have also recently weighed in on the stock. HC Wainwright reaffirmed a neutral rating on shares of GlycoMimetics in a research note on Monday, May 6th. Capital One Financial cut shares of GlycoMimetics from an overweight rating to an equal weight rating in a report on Monday, May 6th.
Read Our Latest Analysis on GlycoMimetics
GlycoMimetics Price Performance
GlycoMimetics (NASDAQ:GLYC – Get Free Report) last posted its quarterly earnings results on Wednesday, March 27th. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. The business had revenue of $0.01 million during the quarter. Analysts expect that GlycoMimetics will post -0.63 EPS for the current year.
Institutional Investors Weigh In On GlycoMimetics
Several institutional investors and hedge funds have recently made changes to their positions in GLYC. Acuta Capital Partners LLC acquired a new position in GlycoMimetics during the third quarter worth about $41,000. MJP Associates Inc. ADV acquired a new position in shares of GlycoMimetics during the 4th quarter worth approximately $238,000. Advisor OS LLC purchased a new stake in GlycoMimetics in the 4th quarter valued at approximately $238,000. Finally, Vanguard Group Inc. grew its holdings in GlycoMimetics by 14.0% during the 1st quarter. Vanguard Group Inc. now owns 2,761,981 shares of the biotechnology company’s stock valued at $8,286,000 after buying an additional 340,112 shares during the last quarter. 75.19% of the stock is currently owned by hedge funds and other institutional investors.
GlycoMimetics Company Profile
GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.
Featured Articles
- Five stocks we like better than GlycoMimetics
- How to Invest in the Best Canadian Stocks
- NASDAQ 100 vs. NASDAQ Composite: A Detailed Breakdown of NASDAQ
- What is the FTSE 100 index?
- These 2 Retail Traders Favorites are Nearing Major Breakouts
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Snowflake is Melting… Up, With a Double-Digit Upside Potential
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.